Pfizer Inc.
PFEHealthcareNASDAQDrug Manufacturers - General · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Pfizer Inc. focuses on Drug Manufacturers - General services and products. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The $171.16B market capitalization puts PFE squarely in large-cap range for its industry. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
Market Cap
$171.16B
Beta
0.28
P/E (TTM)
39.00
P/E (Fwd)
10.41
EPS (TTM)
$0.77
EPS (Fwd)
$2.88
ROE
5.0%
ROA
5.8%
Cash
$11.70B
Total Debt
$63.48B
Free CF
$12.49B
52W Change
21.2%
Annual Financials
Cash vs Debt
Where PFE stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, PFE finished 12.77% above its 150-day moving average ($26.23) and 13.64% above its 200-day moving average ($26.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PFE overbought or oversold?
At the October 19, 2026 close, PFE's RSI(14) was 61.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, PFE has $11.70B in cash with $63.48B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $12.49B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 5.0%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has pulled back from $101.17B (2022) to $62.58B (2025), a 38% decline worth watching.
With a beta below 0.7, Pfizer Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing PFE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.